Vaccines including but not limited to: hepatitis a, hepatitis b, combined hepatitis a and b, mmrmeasles, mumps, rubella, tdtetanus, diphtheria, tdaptetanus, diphtheria and pertussis, meningitis,…
Ended Awarded Last action
- Contract number
- 15F06721F0000461
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Headquarters Division
Federal Bureau of Investigation, Department of Justice
- Obligated
- $115,000
Award facts
- Contract value 100% obligated
- $115,001.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Modification | $115,000 | |
| Other Administrative Action | $49,608 |
About this award
This federal contract award to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, is for the provision of various vaccines including but not limited to hepatitis, measles, mumps, rubella, tetanus, diphtheria, meningitis, rabies, polio, and yellow fever. The contract is a Blanket Purchase Agreement (BPA) call with a firm fixed price, with no set-aside designation. The potential value of the award is $115,001.00, and the period of performance runs from the award date of January 12, 2021 through January 11, 2022. The contracting agency is the Department of Justice Federal Bureau of Investigation Headquarters Division, and the place of performance is Research Triangle Park, North Carolina. Glaxosmithkline has a history of providing pharmaceuticals and vaccines to various U.S. government agencies, supporting disease prevention, immunization programs, and correctional healthcare services.
Description
Vaccines including but not limited to: hepatitis a, hepatitis b, combined hepatitis a and b, mmrmeasles, mumps, rubella, tdtetanus, diphtheria, tdaptetanus, diphtheria and pertussis, meningitis, rabies, polio, typhoid injectable and oral, yellow FEV
Quick answers
Who was awarded contract 15F06721F0000461?
15F06721F0000461 was awarded to Glaxosmithkline, LLC by Headquarters Division (Federal Bureau of Investigation) on January 12, 2021.
How much is contract 15F06721F0000461 worth?
The government has obligated $115,000 on 15F06721F0000461. Its current value, with exercised options, is $115,001.
Is contract 15F06721F0000461 an order under another contract?
Yes. 15F06721F0000461 is a BPA call under DJF171200S0002594, a blanket purchase agreement.
Was contract 15F06721F0000461 competed?
The extent of competition for 15F06721F0000461 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award